<DOC>
	<DOCNO>NCT01191320</DOCNO>
	<brief_summary>The purpose study determine effect investigative drug glycemic control men type 2 diabetes mellitus ( T2DM ) secondary hypogonadism</brief_summary>
	<brief_title>Study Evaluate Efficacy Androxal Controlling Blood Glucose Men With Type-2 Diabetes Mellitus</brief_title>
	<detailed_description>A phase IIB , multi-center , randomize , parallel , placebo- active-controlled trial adult male subject secondary hypogonadism treat OHAs glycemic control . All subject currently treat exogenous testosterone discontinue screen least 21 day remain testosterone course study . One hundred twenty 150 subject randomly assign one three treatment group accord 1:1:1 ratio . Subjects receive one two dose strength Androxal placebo addition usual dose mono- combination OHAs three month . Following initial screening period , subject return monthly 3 month 1 month later follow-up visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<criteria>Males , age 20 80yearsold , inclusive A diagnosis type 2 diabetes mellitus American Diabetes Association ( ADA ) criteria least 6 month Treatment stable suboptimum dose OHAs least 2 month prior screen base lack control blood glucose Previous diagnosis adultonset idiopathic hypogonadotropic hypogonadism ( AIHH ) undergone treatment topical testosterone gel , Lowtoborderline morning total testosterone ( TT ) , least two week washout period , normal low normal serum luteinizing hormone ( LH ) screen baseline No previous diagnosis AIHH present naïve patient low morning TT normal low normal serum LH screen baseline Body Mass Index ( BMI ) 26 40 kg/m2 Fasting blood ( plasma serum ) glucose ( FBG ) 125 240 mg/dL HemoglobinA1c serum ( HbA1c ) 7 % 9.5 % Comprehends informed consent Otherwise normal healthy male All clinical laboratory test within normal range ( deviation outside normal range require approval investigator ) Ability complete study compliance protocol Ability understand provide write informed consent A history testicular failure , Kallmann Syndrome infertility condition Clinically significant medical condition render subject infertile include tumor pituitary , laboratory abnormality , receive investigational drug past 30 day prior study Prostate nodule induration , history , know , suspect prostate cancer rule negative biopsy , prostate specific antigen ( PSA ) high 3.5 ; Hematocrit excess 47 % hemoglobin ( Hb ) great 16 g/dl Previous treatment androgen , estrogen , DHEA , testosterone testosterone analogues injectable , oral , topical form treatment AIHH discontinue start treatment phase ; Primary hypogonadism typify serum LH great 15 TT value le 300 ng/dL Continuous use corticosteroid History current diagnosis major macrovascular complication T2DM : myocardial infarction ( MI ) stroke within 6 month , history coronary revascularization , unstable angina , congestive heart failure ( CHF ) New York Heart Association ( NYHA ) great equal 2 Uncontrolled sit blood pressure ( BP ) great 150/95 , serum creatinine ( Cr ) great 1.5 ULN estimate glomerular filtration rate ( eGFR ) less mL/min/1.73 m2 Retinopathy require continue ophthalmologic assessment Cataracts Other significant history diabetic complication ( proteinuria great 1 g/d , retinopathy , clear neuropathy ) Aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase great 3 time upper limit normal ( ULN ) Total bilirubin great 2.0 mg/dL ( &gt; 34 µmol/L ) ; Injectable testosterone within 120 day Screening ( Visit 1 ) Reported substance abuse screen Taking insulin therapy ; Clinically significant abnormal finding screen examination determine investigator Known hypersensitivity clomiphene citrate ; Current history breast cancer Any condition opinion investigator would interfere participant 's ability provide inform consent , comply study instruction , possibly confound interpretation study result , endanger participant take part study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Adult onset hypogonadotropic hypogonadism</keyword>
</DOC>